Novo Nordisk

News

Novo Nordisk weakens again on interim results readout

Novo Nordisk's already depressed share price has fallen again this morning, despite reporting an 18% increase in sales in the first half of this year.

News

Noom Med app and accompanying GLP-1 implements

Noom expands its GLP-1 range with 'microdose' package

Noom is offering 'microdoses' of semaglutide at a knock-down price, claiming they can prevent side effects but remain effective for weight loss.

News

Lilly trumpets heart health data with Mounjaro

Eli Lilly has raised the stakes in its rivalry with Novo Nordisk on GLP-1 drugs for diabetes, with new data for Mounjaro on cardiovascular outcomes.

News

Novo Nordisk slumps as it cuts sales forecast, names new CEO

Novo Nordisk has a new CEO, facing an uphill battle to restore the fortunes of its US business as diabetes and obesity drugs come under pressure.

News

Novo Nordisk files high-dose Wegovy in EU

Novo Nordisk has moved quickly to file for approval of a higher-dose version of obesity drug Wegovy as it fends off stiff competition from Eli Lilly.

Market Access

Interview at BIO 2025 with Kyle Touchstone and Laura Rowley

Biotech opportunities in North Carolina, with Kyle Touchston...

From BIO 2025: Kyle Touchstone, director of Economic Development Raleigh and Laura Rowley, director of life sciences development for NCBiotech.

Novo Nordisk weakens again on interim results readout

Noom expands its GLP-1 range with 'microdose' package

Lilly trumpets heart health data with Mounjaro

Novo Nordisk slumps as it cuts sales forecast, names new CEO

Novo Nordisk files high-dose Wegovy in EU

Biotech opportunities in North Carolina, with Kyle Touchston...

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

Novo Nordisk

Editor's Picks